Abstract
Background The population prevalence of multimorbidity (the existence of at least 2 or more long-term conditions (LTCs) in an individual) is increasing among young adults, particularly in minority ethnic groups and individuals living in socioeconomically deprived areas. In this study, we applied a data-driven approach to identify clusters of individuals who had an early onset multimorbidity in an ethnically and socioeconomically diverse population. We identified associations between clusters and a range of health outcomes.
Methods and findings We analysed the electronic health records from 837,869 individuals in England with early onset multimorbidity (aged between 16 and 39 years old when the second LTC was recorded) using linked primary and secondary care data between 2010 and 2020 from the Clinical Practice Research Datalink GOLD (CPRD GOLD). A total of 204 LTCs were included. Latent class analysis stratified by ethnicity unveiled 4 clusters of multimorbidity in White groups and 3 clusters in South Asian and Black groups. We found that early onset multimorbidity is the most common form of multimorbidity among minority ethnic (59% and 56%, in the South Asian and Black populations, respectively) in the UK compared to the White population (42%). At the end of the study, 4% of the White early onset multimorbidity population had died compared to 2% of the South Asian and Black populations, however, the latter groups died younger and lost more years of life. The three ethnic groups displayed a cluster of individuals with increased rates of primary care consultations, hospitalisations, long-term prescribing, and odds of mortality. These presented a combination of physical and mental health conditions that are common across all groups (hypertension, depression and painful conditions being the leading conditions). However, they also presented exclusive LTCs and had different sociodemographic profiles: Whites were mostly men (54%), South Asian and Black groups were more socioeconomically deprived than White groups, with a consistent deprivation gradient across all multimorbidity clusters. In White groups, the highest risk cluster was more socioeconomically deprived than the lowest risk cluster.
Conclusions These findings emphasise the need to identify, prevent and manage multimorbidity early in the life course. Our work provides additional insights into the need to ensure healthcare improvements are equitable and reach those from socioeconomically deprived and diverse groups who are disproportionately and more severely affected by multimorbidity.
Competing Interest Statement
MS is funded by AIM-MULTIPLY Consortium (NIHR203982) RH is funded by the Health Data Research UK (grant ref: LOND1). MM does not have any competing interests or funding to declare TA is funded by the NIHR Applied Research Collaboration North Thames Award (NIHR 200163). RHMW has received fees from American Center for Psychiatry & Neurology United Arab Emirates, British Association for Psychopharmacology, European College of Neuropsychopharmacology, International Society for Affective Disorders, Janssen, LivaNova, Lundbeck, My Tomorrows, OCM Comunicaziona s.n.c., Pfizer, Qatar International Mental Health Conference, Sunovion, Syntropharma, UK Medical Research Council and Wiley; grant support from National Institute for Health Research Efficacy and Mechanism Evaluation Panel and Health Technology Assessment Panel; and non-financial support from COMPASS Pathways and Magstim. PM is funded by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre, by NIHR AIM AI-MULTIPLY, and by NIHR ADMISSION (MR/V033654/1) NJR is funded by the National Institute for Health Research (NIHR) Newcastle Biomedical Research Centre, by the NIHR Newcastle In Vitro Diagnostics Co-operative and NIHR AIM AI-MULTIPLY. N.J.R. is also a NIHR Senior Investigator, (Senior Investigator Award) NIHR200168. NJR reports grants from PSORT industrial partners as listed (http://www.psort.org.uk/); other research grants from GSK Stiefel and Novartis. MRB is funded by the National Institute for Health Research (NIHR) AIM AI-MULTIPLY Consortium (NIHR203982). MRB reports research grants from Benevolent AI, Janssen and Novartis. This work (and salary costs to SF, RM, SH, FE) was supported by MRC (MR/S027297/1). Multimorbidityclusters, trajectories and genetic risk in British south Asians, 2020-2023. Additional support for this and related work (SF, MRB, NJR, PM, RHM, RH, AA, MS, FE) is from NIHR 31672 AI-MULTIPLY, 2022-2025, and NIHR 202635 (SF, NJR, MRB, PM). SF and RM receive salary contributions for their work on the Genes & Health programme, by a Life Sciences Consortium that includes Astra Zeneca PLC, Bristol-Myers Squibb Company, GlaxoSmithKline Research and Development Limited, Maze Therapeutics Inc, Merck Sharp & Dohme LLC, Novo Nordisk A/S, Pfizer Inc, Takeda Development Centre Americas Inc. RM is supported by Barts Charity (MGU0504). RM has received consulting fees from AMGEN unrelated to this work.
Funding Statement
This work (and salary costs to SF, RM, SH, FE) was supported by MRC (MR/S027297/1). Multimorbidityclusters, trajectories and genetic risk in British south Asians, 2020-2023. Additional support for this and related work (SF, MRB, NJR, PM, RHM, RH, AA, MS, FE) is from NIHR 31672 AI-MULTIPLY, 2022-2025, and NIHR 202635 (SF, NJR, MRB, PM).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This study was approved by the Independent Scientific Advisory Board for Medicines and Healthcare products Regulatory Agency research (protocol reference 21_000345). No further ethics approval is required.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
(f.eto{at}qmul.ac.uk)
(m.samuel{at}qmul.ac.uk)
(r.henkin{at}qmul.ac.uk)
(m.mahesh{at}smd18.qmul.ac.uk)
(t.a.ahmad{at}qmul.ac.uk)
(a.angdembe{at}qmul.ac.uk)
(hamish.mcallister-williams{at}newcastle.ac.uk)
(paolo.missier{at}newcastle.ac.uk)
(nick.reynolds{at}newcastle.ac.uk)
(m.r.barnes{at}qmul.ac.uk)
(s.a.hull{at}qmul.ac.uk)
(s.finer{at}qmul.ac.uk)
(r.mathur{at}qmul.ac.uk)
Data Availability
The study uses data from the Clinical Practice Research Datalink (CPRD). CPRD does not allow the sharing of patient-level data. The data specification for the CPRD data set is available at: https://www.cprd.com/sites/default/files/CPRD_GOLD_Full_Data_Specification_v2.0_0.pdf. Additional information on the IMD patient-level linkage data is available at: https://cprd.com/sites/default/files/Documentation_SmallAreaData_Patient_set18_v2.7.pdf. The code list used in this study are available at https://github.com/f-eto/MULTIPLY-Initiative
